References
- Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J. C., Guglieri, S., Fraser, B., Al-Hakim, A., Gunay, N. S., Zhang, Z., Robinson, L., Buhse, L., Nasr, M., Woodcock, J., Langer, R., Venkataraman, G., Linhardt, R. J., Casu, B., Torri, G. and Sasisekharan, R. (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 26: 669-675 https://doi.org/10.1038/nbt1407
- Li, B., Suwan, J., Martin, J. G., Zhang, F., Zhang, Z., Hoppensteadt, D., Clark, M., Fareed, J. and Lindhardt, R. J. (2009) Oversulfated chondroitin sulfate interaction with heparin-binding proteins: New insights into adverse reactions from contaminated heparins. Biochem. Pharamcol. 78: 292-300 https://doi.org/10.1016/j.bcp.2009.04.012
- Maruyama, T., Toida, T., Imanari, T., Yu, G. and Linhardt, R. J. (1998) Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 306: 35-43 https://doi.org/10.1016/S0008-6215(97)10060-X
- Kishimoto, T. K., Viswanathan, K., Ganguly, T., Elankumaran, S., Smith, S., Pelzer, K., Lansing, J. C., Sriranganathan, N., Zhao, G., Galcheva-Gargova, Z., Al-Hakim, A., Bailey, G. S., Fraser, B., Roy, S., Rogers-Cotrone, T., Buhse, L., Whary, M., Fox, J., Nasr, M., Dal Pan, G. J., Shriver, Z., Langer, R. S., Venkataraman, G., Austen, K. F., Woodcock, J. and Sasisekharan, R. (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 308: 2457-2467 https://doi.org/10.1056/NEJMoa0803200.
- Blossom, D. B., Kallen, A. J., Patel, P. R., Elward, A., Robinson, L., Gao, G., Langer, R., Perkins, K. M., Jaeger, J. L., Kurkjian, K. M., Jones, M., Schillie, S. F., Shehab, N., Ketterer, D., Venkataraman, G., Kishimoto, T. K., Shriver, Z., McMahon, A. W., Austen, K. F., Kozlowski, S., Srinivasan, A., Turabelidze, G., Gould, C. V., Arduino, M. J. and Sasisekharan, R. (2008) Outbreak of adverse reactions associated with contaminated heparin. ibid 359: 2674-2684
- Liu, H., Zhang, Z. and Linhardt, R. J. (2009) Lessons learned from the contamination of heparin. Nat. Prod. Rep. 26: 313-321 https://doi.org/10.1039/b819896a
- Han, Y. H., Garron, H. L., Kim, H. Y., Kim, W., Zhang, Z., Ryu, K. S., Shaya, D., Xiao, Z., Cheong, C., Kim, Y. S., Linhardt, R. J., Jeon, Y. H. and Cygler, M. J. Biol. Chem. submitted (under revision)
- Rice, K. G., Rottink M. K. and Linhardt, R. J. (1987) Fractionation of heparin-derived oligosaccharides by gradient polyacrylamide-gel electrophoresis. Biochem. J. 244: 515-522
- Zhang, Z., Weiwer, M., Li, Boyangzi., Kemp, M. M., Daman, T. H. and Linhardt, R. J. (2008) Oversulfated Chondroitin sulfate: Impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J. Med. Chem 51: 5498-5501 https://doi.org/10.1021/jm800785t
-
Beyer, T., Diehl, B., Randel, G., Humpfer, E., Schafer, H., Spraul, M., Schollmayer, C. and Holzgrabe, U. (2008) Quality assessment of unfractionated heparin using
$^1H$ nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 48: 13-19 https://doi.org/10.1016/j.jpba.2008.06.014 - Tollefsen, D. M., Majerus, D. W. and Blank, M. K. (1982) Heparin cofactor II, Purification and properties of a heparindependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257: 2162-2169
- Tollefsen, D. M., Pestka, C. A. and Monafo, W. J. (1983) Activation of heparin cofactor II by dermatan sulfate. ibid, 258: 6713-6716
- Kyogashinma, M., Onaya, J., Miyauchi, S., Arai, M., Shibata, Y., Suda, A., Sakai, T., Takada, Y. and Takada, A. (1999) Antithrombotic activity of avian crown dermatan sulfate. Thromb. Res. 96: 459-465 https://doi.org/10.1016/S0049-3848(99)00138-3
- Fernandez, F., Van Ryn, J., Ofosu, F. A., Hirsh, J. and Buchanan, M. R. (1986) The harmorrhagic and antithrombotic effects of dermatan sulphate. Brit. J. Haemotol. 64: 309-317 https://doi.org/10.1111/j.1365-2141.1986.tb04124.x